Zantac Tablets 300mg

  • Name:

    Zantac Tablets 300mg

  • Company:
    info
  • Active Ingredients:

    Ranitidine Hydrochloride

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 11/11/16

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 11/11/2016
print

Print ViewKeyword Search SmPC

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Amoxil Paediatric Suspension Active Ingredients Amoxicillin trihydrate
Medicine Name Amoxil Vial for Injection 500mg Active Ingredients Amoxicillin sodium
Medicine Name ANORO ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed Active Ingredients Umeclidinium bromide, Vilanterol trifenatate
Medicine Name Augmentin 250 mg/125 mg film-coated tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 500mg/125mg Film-coated Tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 875/125mg Film Coated tablets Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin Duo Mixed Fruit 400 mg/57 mg /5 ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin DUO Suspension 400/57mg Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin Intravenous 1.2g Active Ingredients Amoxicillin sodium, Potassium clavulanate
Medicine Name Augmentin Paediatric 125mg/31.25mg per 5ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name AVAMYS 27.5 micrograms/spray nasal spray suspension Active Ingredients Fluticasone furoate
Medicine Name Avodart Soft Capsules 0.5mg Active Ingredients Dutasteride
Medicine Name Babyhaler Active Ingredients No Active Ingredients
Medicine Name Bactroban Nasal Ointment Active Ingredients Mupirocin calcium
Medicine Name Bactroban Ointment Active Ingredients Mupirocin
Medicine Name Becotide Evohaler 100 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 250 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 50 Active Ingredients Beclometasone Dipropionate
Medicine Name Benlysta 120 mg and 400 mg powder for concentrate for solution for infusion Active Ingredients Belimumab
Medicine Name Betnovate C 0.1% / 3% w/w Cream Active Ingredients Betamethasone Valerate, Clioquinol
Medicine Name Betnovate Cream 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Ointment 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Cream Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Ointment Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Scalp Application 0.1% w/v Cutaneous Solution Active Ingredients Betamethasone Valerate
1 - 25 of 135 items.Total: 6 pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 11 November 2016 PIL

Reasons for updating

  • Change to section 5 - how to store or dispose
  • Change to section 6 - date of revision

Updated on 11 November 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 11 November 2016 SmPC

Reasons for updating

  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Store below 25oC. Store in the original package in order to protect from moisture.

Updated on 11 November 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 22 July 2015 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to address of the Irish MA Holder

Updated on 22 July 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 17 June 2015 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text
  • Change to improve clarity and readability

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4: H2 receptor antagonists changed to ranitidine alone.
Section 4.5: Amended to include information on interaction between ranitidine and amoxicillin and metronidazole.
Section 4.8: Dyspnoea included as unknown adverse event under Immune System Disorders. Tachycardia added as very rare adverse event under Cardiac Disorders. Nephropatic patients referenced under Psychiatric Disorders. Paediatric subheading and adverse event reporting details included

Updated on 16 June 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to side-effects
  • Change to drug interactions
  • Change to date of revision
  • Change to improve clarity and readability
  • Addition of information on reporting a side effect.

Updated on 2 May 2014 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.2

Update re treatment for patients with reflux oesophagitis

4.3

Update to statement for hypersensitivity

4.4

Update to the warnings

4.5

Change to the information regarding one of the medicines that interacts

4.6

Rewording of this section

5.1

Add the therapeutic group

Updated on 16 January 2012 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 10 June 2011 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.2       Posology and Method of Administration

 

 

 

Renal Insufficiency:

 

In patients with a creatinine clearance < 50ml/min the usual dose is 150mg nightly.  In patients on dialysis, dosage should be given on completion of dialysis.

Accumulation of ranitidine with resulting elevated plasma concentrations will occur in patients with renal impairment (creatinine clearance less than 50 ml/min). It is recommended that the daily dose of ranitidine in such patients should be 150 mg.

**************************************************************

 

4.4  Special warnings and precautions for use

 

Before initiation of ranitidine treatment for any gastric ulceration, malignancy should be excluded by endoscopy and biopsy if possible.  Treatment may mask the symptoms of malignancy, delaying diagnosis.

 

Ranitidine is excreted via the kidney and so plasma levels of the drug are increased in patients with severe renal impairment, adjust dosage detailed under section 4.2 above.

 

Regular supervision of patients who are taking non-steroidal anti-inflammatory drugs concomitantly with ranitidine is recommended, especially in the elderly and in those with a history of peptic ulcer.

 

In patients such as the elderly, persons with chronic lung disease, diabetes orf the immunocompromised, there may be an increased risk of developing community acquired pneumonia. A large epidemiological study showed an increased risk of developing community acquired pneumonia in current users of H2 receptor antagonistsranitidine alone versus those who had stopped treatment, with an observed adjusted relative risk of 1.63 (95% CI, 1.07-2.48)increase of 1.82 (95% CI 1.26 – 2.64).

 

**************************************************************

 

 

4.6  Fertility, Ppregnancy and lactation

 

**************************************************************

 

4.8  Undesirable effects

 

 

Gastrointestinal Disorders

Very Rare:       Acute pancreatitis. Diarrhoea.

Uncommon:     Abdominal pain, constipation, nausea (these symptoms mostly improved during continued treatment)

 

 

Renal and Urinary Disorders

Very rare:        Acute interstitial nephritis.

Rare:                Elevation of plasma creatinine (usually slight; normalised during continued treatment).

 

Reproductive System and Breast Disorders

Very Rare:       Reversible impotence. Breast symptoms in men, breast symptoms and breast conditions (such as gynaecomastia and galactorrhoea)

 

**************************************************************

 

5.  PHARMACOLOGICAL PROPERTIES

 

 

5.2  Pharmacokinetic properties

 

The bioavailability of ranitidine is consistently about 50%.  Peak concentrations in plasma, normally in the range 300-550ng/ml, occur 2-3 hours after oral administration of a 150mg dose.  Concentrations of ranitidine in plasma are proportional to dose up to and including 300mg.  Ranitidine is not extensively metabolised.  Elimination of the drug is primarily by tubular secretion.  The elimination half-life is 2-3 hours.  In balance studies with 150mg 3H-ranitidine 93% of an intravenous dose was excreted in urine and 5% in faeces; 60-70% of an oral dose was excreted in urine and 26% in faeces. 

 

Analysis of urine excreted in the first 24 hours after dosing showed that 70% of the intravenous dose and 35% of the oral dose were eliminated unchanged. 

 

The metabolism of ranitidine is similar after both oral and intravenous dosing; about 6% of the dose being excreted in urine as the N-oxide, 2% as the S-oxide, 2% as desmethylranitidine and  1 - 2% as the furoic acid analogue.

 

Absorption:

Following oral administration of 150 mg ranitidine, maximum plasma concentrations (300 to 550 ng/mL) occurred after 1-3 hours. Two distinct peaks or a plateau in the absorption phase result from reabsorption of drug excreted into the intestine. The absolute bioavailability of ranitidine is 50-60%, and plasma concentrations increase proportionally with increasing dose up to 300 mg.

 

Distribution:

Ranitidine is not extensively bound to plasma proteins (15%), but exhibits a large volume of distribution ranging from 96 to 142 L.

 

Metabolism:

Ranitidine is not extensively metabolised. The fraction of the dose recovered as metabolites is similar after both oral and i.v. dosing; and include 6% of the dose in urine as N-oxide, 2% as the S-oxide, 2% as desmethylranitidine and 1 to 2% as the furoic acid analogue.

 

Elimination:

Plasma concentrations decline bi-exponentially, with a terminal half-life of 2-3 hours. The major route of elimination is renal. After IV administration of 150 mg 3H-ranitidine, 98% of the dose was recovered, including 5% in faeces and 93% in urine, of which 70% was unchanged parent drug. After oral administration of 150 mg 3H-ranitidine, 96% of the dose was recovered, 26% in faeces and 70% in urine, of which 35% was unchanged parent drug. Less than 3% of the dose is excreted in bile. Renal clearance is approximately 500 mL/min, which exceeds glomerular filtration indicating net renal tubular secretion.

 

Updated on 20 April 2010 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.1  Therapeutic indications

 

In the treatment of duodenal ulcer and benign gastric ulcer including that associated with non-steroidal anti-inflammatory agents.  Prevention of non-steroidal anti-inflammatory drug (including aspirin) associated duodenal ulcers, especially in patients with a history of peptic ulcer disease.  Zantac Tablets are also indicated for treatment of post-operative ulcer, reflux oesophagitis, Zollinger-Ellison syndrome and other conditions where reduction of gastric acid secretion is likely to be beneficial.

 

Children (3 to 18 years)

 

·                Short term treatment of peptic ulcer

·                Treatment of gastro-oesophageal reflux, including reflux oesophagitis and symptomatic relief of gastro-oesophageal reflux disease.

 

4.2       Posology and Method of Administration

 

Adults (including the elderly) / Adolescents (12 years and over)

 

The usual initial dosage is 150mg bd or 300mg nocte.  This may be increased to ranitidine 300mg twice daily without an increased incidence of unwanted effects.  Subsequently a maintenance dose of 150mg nocte may be used.  Smoking is associated with a higher rate of ulcer relapse, and such patients should be advised to stop smoking.  In those who fail to comply with such advice, a dose of 300mg at night provides additional therapeutic benefit over the standard dose.

 

In most cases of duodenal ulcer, benign gastric ulcer and post operative ulcer, healing occurs within 4 weeks.  Healing usually occurs after a further 4 weeks in those not fully healed after the initial 4 weeks.  In ulcers following non-steroidal anti-inflammatory drug therapy, 8 - 12 weeks treatment may be necessary.  For the prevention of non-steroidal anti-inflammatory drug associated duodenal ulcers ranitidine 150mg bd may be given concomitantly with non-steroidal anti-inflammatory drug therapy.

 

In the management of reflux oesophagitis the usual course of treatment is either 150mg twice daily or 300mg at night administered for up to a period of 8, or if necessary 12 weeks.  In patients with moderate to severe oesophagitis the dosage may be increased to 150mg four times daily, alternatively 300mg twice a day, if necessary.

 

For the long-term management of reflux oesophagitis, the recommended adult oral dose is 150mg twice daily for the prevention of relapse in patients with reflux oesophagitis.  Zantac 150mg effervescent tablets are not indicated in patients with complications of reflux oesophagitis e.g. severe oesophegeal stricture or Barratt’s oesophagus.

 

In keeping with the recommended clinical practice it is advisable that patients on long-term maintenance therapy receive regular routine assessment by practitioners.

 

In patients with Zollinger-Ellison syndrome the starting dose is 150mg thrice daily, increased as necessary up to a maximum of 6 grams daily.

 

In the prophylaxis of haemorrhage from stress ulceration in seriously ill patients or the prophylaxis of recurrent haemorrhage in patients bleeding from peptic ulceration, treatment with Zantac 150mg twice daily may be substituted for Zantac Injection once oral feeding commences in patients considered to be still at risk from these conditions.

 

In obstetric patients an oral dose of 150mg may be given at commencement of labour, followed by 150mg at 6 hourly intervals.  It is recommended that in addition, a non-particulate antacid (eg sodium citrate) should be given prior to induction of anaesthesia in any patient requiring emergency general anaesthesia.

 

Children from 3 to 11 years and over 30 kg of weight

 

See section 5.2 Pharmacokinetic properties – Special Patient Populations.

 

Peptic Ulcer Acute Treatment

 

The recommended oral dose for the treatment of peptic ulcer in children is 4 mg/kg/day to 8 mg/kg/day administered as two divided doses to a maximum of 300 mg ranitidine per day for a duration of 4 weeks. For those patients with incomplete healing, another 4 weeks of therapy is indicated, as healing usually occurs after eight weeks of treatment.

 

Gastro-Oesophageal Reflux

 

The recommended oral dose for the treatment of gastro-oesophageal reflux in children is 5 mg/kg/day to 10 mg/kg/day administered as two divided doses in a maximum dose of 600 mg (the maximum dose is likely to apply to heavier children or adolescents with severe symptoms).

 

Safety and efficacy in new-born patients has not been established

 

The recommended oral dose for the treatment of peptic ulcer in children is 2mg/kg to 4mg/kg twice daily to a maximum of 300mg ranitidine per day.

 

4.5  Interaction with Other Medicaments and Other Forms of Interaction

 

Ranitidine has the potential to affect the absorption, metabolism or renal excretion of other drugs.  The altered pharmacokinetics may necessitate dosage adjustment of the affected drug or discontinuation of treatment.

 

Interactions occur by several mechanisms including:

 

1) Inhibition of cytochrome P450-linked mixed function oxygenase system:

Ranitidine at usual therapeutic doses does not potentiate the actions of drugs which are inactivated by this enzyme system such as diazepam, lidocaine, phenytoin, propranolol and theophylline. 

There have been reports of altered prothrombin time with coumarin anticoagulants (e.g. warfarin). Due to the narrow therapeutic index, close monitoring of increased or decreased prothrombin time is recommended during concurrent treatment with ranitidine.

 

2) Competition for renal tubular secretion:

Since ranitidine is partially eliminated by the cationic system, it may affect the clearance of other drugs eliminated by this route.  High doses of ranitidine (e.g such as those used in the treatment of Zollinger-Ellison syndrome) may reduce the excretion of procainamide and N-acetylprocainamide resulting in increased plasma levels of these drugs.

 

3) Alteration of gastric pH:

The bioavailability of certain drugs may be affected.  This can result in either an increase in absorption (e.g. triazolam, midazolam) or a decrease in absorption (e.g. ketoconazole, atazanavir, glipizide, delaviridine, gefitnib).

 

Ranitidine, at blood levels produced by standard recommended doses, does not inhibit the hepatic cytochrome P450-linked mixed function oxygenase system.  Accordingly, ranitidine in the usual therapeutic dose does not potentiate the actions of drugs which are inactivated by this enzyme; these include diazepam, lignocaine, phenytoin, propranolol, theophylline and warfarin.

 

……………………………..

4.8  Undesirable effects

 

The following convention has been utilised for the classification of undesirable effects: very common (>1/10), common (>1/100, <1/10), uncommon (>1/1000, <1/100), rare (>1/10,000, <1/1000), very rare (1/10,000).

……………………………..

 

Reproductive System and Breast Disorders

Very Rare:       Reversible impotence. Breast symptoms in men

 

The safety of ranitidine has been assessed in children aged 0 to 16 years with acid-related disease and was generally well tolerated with an adverse event profile resembling that in adults. There are limited long term safety data available, in particular regarding growth and development.

……………………………..

5.2  Pharmacokinetic properties

 

The bioavailability of ranitidine is consistently about 50%.  Peak concentrations in plasma, normally in the range 300-550ng/ml, occur 2-3 hours after oral administration of a 150mg dose.  Concentrations of ranitidine in plasma are proportional to dose up to and including 300mg.  Ranitidine is not extensively metabolised.  Elimination of the drug is primarily by tubular secretion.  The elimination half-life is 2-3 hours.  In balance studies with 150mg 3H-ranitidine 93% of an intravenous dose was excreted in urine and 5% in faeces; 60-70% of an oral dose was excreted in urine and 26% in faeces. 

 

Analysis of urine excreted in the first 24 hours after dosing showed that 70% of the intravenous dose and 35% of the oral dose were eliminated unchanged. 

 

The metabolism of ranitidine is similar after both oral and intravenous dosing; about 6% of the dose being excreted in urine as the N-oxide, 2% as the S-oxide, 2% as desmethylranitidine and  1 - 2% as the furoic acid analogue.

 

Special Patient Populations

 

Children (3 years and above)

 

Limited pharmacokinetic data have shown that there are no significant differences in half-life (range for children 3 years and above: 1.7 - 2.2 h) and plasma clearance (range for children 3 years and above: 9 - 22 ml/min/kg) between children and healthy adults receiving oral ranitidine when correction is made for body weight.

 

10.  DATE OF (PARTIAL) REVISION OF THE TEXT

 

March 2010

Updated on 31 March 2010 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to dosage and administration

Updated on 25 August 2009 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Improved electronic version

Updated on 29 October 2008 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 24 September 2008 PIL

Reasons for updating

  • Change to date of revision
  • Change to improve clarity and readability

Updated on 22 September 2008 SmPC

Reasons for updating

  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

 

New Date of last Renewal: 1st December 2007

Updated on 21 May 2008 SmPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.6 - Special precautions for disposal and other handling

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

 

5.1  (Pharmacodynamic properties). The following section has been added: In patients such as the elderly, persons with chronic lung disease, diabetes of the immunocompromised, there may be an increased risk of developing community acquired pneumonia. A large epidemiological study showed an increased risk of developing community acquired pneumonia in current users of H2 receptor antagonists versus those who had stopped treatment, with an observed adjusted relative risk of 4.63 (95% CI, 1.07-2.48)

 

6.6 (Instructions for use/handling) “none” has been deleted andNo special requirements” has been added.

Updated on 19 June 2007 SmPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

5.1 Pharmacodynamic properties

 

Pharmacotherapeutic group: Alimentary tract and metabolism.

ATC code: A02 BA02.

 

Zantac is a specific, rapidly acting histamine H2-antagonist.  It inhibits basal and stimulated secretion of gastric acid reducing both the volume and the acid and pepsin content of the secretion.

 

Although no clear casual link has been established, a large epidemiological study showed showed an increased risk of developing community acquired pneumonia in current users of H2 receptor antagonists versus those who had stopped treatment, with an observed adjusted relative risk increase of 1.63 (95% CI, 1.07 – 2.48).  Therefore, in patients with conditions predisposing to the development of pneumonia, such as chronic lung disease, diabetes, or the immunocompromised, there may be an increased risk of developing community acquired pneumonia.

Updated on 23 February 2007 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 11 November 2005 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 31 May 2005 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 22 October 2003 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 19 August 2003 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 25 June 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)